As a realistic alternative to the GRP75-targeting ‘gene therapy’, the cancer-promoting functions of GRP75 can be inhibited by treating breast tumor cells with cell-permeable drugs or peptides which somehow downregulate the GRP75 expression/activity. Here, HSPA9 is linked to breast neoplasm.